Document Detail

Status of uric acid management in hypertensive subjects.
MedLine Citation:
PMID:  17664859     Owner:  NLM     Status:  MEDLINE    
Hyperuricemia in hypertensive subjects has been considered one of risk factors of cardiovascular diseases. We investigated the status of uric acid management in 799 hypertensive subjects (432 females and 367 males; mean age 70.9 years) managed by 43 doctors (19 cardiologists and 24 noncardiologists; 25 private practice doctors and 18 hospital doctors). The serum uric acid level was available in 85.7% of the patients. This availability was equivalent regardless of facility size, and more cardiologists than noncardiologists monitored this information. The prevalence of hyperuricemia was 17.5% and was higher in men and in patients with high triglyceridemia, left ventricular hypertrophy, renal dysfunction, proteinuria, and smokers, but was not higher in subjects with chronic heart failure, diabetes mellitus, and those with prescriptions for diuretics and beta-blockers. The average serum uric acid level was higher in men and patients with chronic heart failure, renal dysfunction, high triglyceridemia, low high-density cholesterolemia, smokers, and subjects prescribed beta-blockers. Fifty percent of hyperuricemic patients were medicated, and 48.6% of them cleared the uric acid target level (6 mg/dL). No differences were observed in the treatment rate or the achievement rate of the target between genders, concurrent diseases, and physician specialties. Although doctors, especially cardiologists, have a high concern for the serum uric acid level, they do not intervene intensively, and specific treatment for individual patterns is not routinely given. Thus, more attention to uric acid management is necessary in hypertensive subjects to prevent cardiovascular diseases.
Yasutaka Yamamoto; Koichi Matsubara; Go Igawa; Yasuhiro Kaetsu; Shinobu Sugihara; Takashi Matsuura; Fumihiro Ando; Kazuhiko Sonoyama; Toshihiro Hamada; Kazuhide Ogino; Osamu Igawa; Chiaki Shigemasa; Ichiro Hisatome
Related Documents :
8878379 - Factors influencing the adequacy of microencapsulation of rat pancreatic islets.
15698589 - Uric acid: an abettor or protector in calcium oxalate urolithiasis? biochemical study i...
10340829 - A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or amm...
8357939 - A high-performance liquid chromatographic method for the determination of hypoxanthine,...
359019 - A double-blind comparison of the effects of hydrochlorothiazide and tienylic acid (a di...
533419 - Capabilities of the redy cartridge for regeneration of hemofiltrate.
6803089 - Prostaglandins and inflammatory reactions in the eye.
8515819 - Interaction between an acidic activator and transcription factor tfiib is required for ...
3150679 - Liberation and oxygenation of polyenoic acids in stimulated platelets.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  30     ISSN:  0916-9636     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-07-31     Completed Date:  2007-09-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  549-54     Citation Subset:  IM    
Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Sciences, Yonago, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Cardiology / statistics & numerical data
Cross-Sectional Studies
Enzyme Inhibitors / therapeutic use
Hypertension / blood*
Hyperuricemia / diagnosis*,  drug therapy,  epidemiology
Institutional Practice / statistics & numerical data
Japan / epidemiology
Physician's Practice Patterns / statistics & numerical data*
Private Practice / statistics & numerical data
Uric Acid / blood*
Uricosuric Agents / therapeutic use
Xanthine Oxidase / antagonists & inhibitors
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Uricosuric Agents; 69-93-2/Uric Acid; EC Oxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in...
Next Document:  Comparison of three measures of the ankle-brachial blood pressure index in a general population.